These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33014444)

  • 1. Corrigendum to "Retrospective Observational Study on Rebamipide Ophthalmic Suspension on Quality of Life of Dry Eye Disease Patients".
    Sakane Y; Yamaguchi M; Shiraishi A
    J Ophthalmol; 2020; 2020():8486704. PubMed ID: 33014444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye.
    Ueda K; Matsumiya W; Otsuka K; Maeda Y; Nagai T; Nakamura M
    BMC Ophthalmol; 2015 Jun; 15():58. PubMed ID: 26048396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Observational Study on Rebamipide Ophthalmic Suspension on Quality of Life of Dry Eye Disease Patients.
    Sakane Y; Yamaguchi M; Shiraishi A
    J Ophthalmol; 2019; 2019():8145731. PubMed ID: 31192001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Rebamipide Ophthalmic Suspension on Intraocular Light Scattering for Dry Eye After Corneal Refractive Surgery.
    Igarashi A; Kamiya K; Kobashi H; Shimizu K
    Cornea; 2015 Aug; 34(8):895-900. PubMed ID: 26020821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye.
    Koh S; Inoue Y; Sugmimoto T; Maeda N; Nishida K
    Cornea; 2013 Sep; 32(9):1219-23. PubMed ID: 23676786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.
    Kinoshita S; Oshiden K; Awamura S; Suzuki H; Nakamichi N; Yokoi N;
    Ophthalmology; 2013 Jun; 120(6):1158-65. PubMed ID: 23490326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of an Ultrafine Rebamipide Ophthalmic Suspension with High Transparency.
    Matsuda T; Hiraoka S; Urashima H; Ogura A; Ishida T
    Biol Pharm Bull; 2017; 40(5):665-674. PubMed ID: 28458352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Comparison Between Rebamipide Ophthalmic Suspension and Diquafosol Ophthalmic Solution for Dry Eye After Penetrating Keratoplasty.
    Kobashi H; Kamiya K; Shimizu K
    J Ocul Pharmacol Ther; 2017; 33(1):13-18. PubMed ID: 27937084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
    Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
    Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: A Rare Orbital Abscess Caused by Dacryocystitis After Administration of Rebamipide Ophthalmic Suspension.
    Imamura H; Eguchi H; Sakamoto M; Hotta F; Tabuchi H; Kusaka S
    Front Med (Lausanne); 2021; 8():646397. PubMed ID: 34447756
    [No Abstract]   [Full Text] [Related]  

  • 11. The Effects of Rebamipide 2% Ophthalmic Solution Application on Murine Subbasal Corneal Nerves After Environmental Dry Eye Stress.
    Simsek C; Kojima T; Nakamura S; Dogru M; Tsubota K
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye.
    Kinoshita S; Awamura S; Nakamichi N; Suzuki H; Oshiden K; Yokoi N;
    Am J Ophthalmol; 2014 Mar; 157(3):576-83.e1. PubMed ID: 24246575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alkali burn treated with 2% rebamipide ophthalmic suspension: a case report.
    Sasaki H; Kokubun T
    Case Rep Ophthalmol; 2014; 5(3):380-5. PubMed ID: 25762927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in Signs and Symptoms of Dry Eye after Instillation of 2% Rebamipide.
    Igarashi T; Fujita M; Yamada Y; Kobayashi M; Fujimoto C; Takahashi H; Igarashi T; Nakano Y; Suzuki H; Takahashi H
    J Nippon Med Sch; 2015; 82(5):229-36. PubMed ID: 26568389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes.
    Hayashi Y; Toshida H; Matsuzaki Y; Matsui A; Ohta T
    Int Med Case Rep J; 2016; 9():113-6. PubMed ID: 27257394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal.
    Kashima T; Itakura H; Akiyama H; Kishi S
    Clin Ophthalmol; 2014; 8():1003-10. PubMed ID: 24940041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of instillation of eyedrops for dry eye on optical quality.
    Koh S; Maeda N; Ikeda C; Takai Y; Fujimoto H; Oie Y; Soma T; Tsujikawa M; Nishida K
    Invest Ophthalmol Vis Sci; 2013 Jul; 54(7):4927-33. PubMed ID: 23812492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rebamipide ophthalmic suspension on the success of lacrimal stent intubation.
    Mimura M; Ueki M; Oku H; Sato B; Ikeda T
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):385-9. PubMed ID: 26483146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes.
    Shrivastava S; Patkar P; Ramakrishnan R; Kanhere M; Riaz Z
    Oman J Ophthalmol; 2018; 11(3):207-212. PubMed ID: 30505109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Rebamipide on Differences in Power and Axis of Corneal Astigmatism Between Two Intra-patient Keratometric Measurements in Dry Eyes.
    Teshigawara T; Meguro A; Mizuki N
    Ophthalmol Ther; 2021 Dec; 10(4):891-904. PubMed ID: 34292514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.